Foghorn Therapeutics Inc
$ 4.74
0.00%
30 Jul - close price
- Market Cap 278,304,000 USD
- Current Price $ 4.74
- High / Low $ 4.83 / 4.61
- Stock P/E N/A
- Book Value -1.30
- EPS -1.17
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -4.70 %
- 52 Week High 6.95
- 52 Week Low 3.27
About
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within the chromatin regulatory system. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$11.44
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-11 | 2025-11-05 | 2025-08-05 | 2025-05-14 | 2025-03-06 | 2024-11-04 | 2024-08-08 | 2024-05-06 | 2024-03-07 | 2023-11-02 | 2023-08-04 |
| Reported EPS | -0.29 | -0.3654 | -0.25 | -0.28 | -0.3 | -0.3 | -0.31 | -0.45 | -0.59 | -0.57 | -0.34 | -0.7 |
| Estimated EPS | -0.31 | -0.2589 | -0.31 | -0.32 | -0.29 | -0.28 | -0.43 | -0.64 | -0.59 | -0.76 | -0.65 | -0.69 |
| Surprise | 0.02 | -0.1065 | 0.06 | 0.04 | -0.01 | -0.02 | 0.12 | 0.19 | 0 | 0.19 | 0.31 | -0.01 |
| Surprise Percentage | 6.4516% | -41.1356% | 19.3548% | 12.5% | -3.4483% | -7.1429% | 27.907% | 29.6875% | 0% | 25% | 47.6923% | -1.4493% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.23 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FHTX
2026-07-30 10:39:58
This article provides financial data for Foghorn Therapeutics Inc. (NASDAQ: FHTX), specifically its price-to-earnings forward metric. It originates from TradingView and indicates that the market was closed at the time of publication, with no trades reported. The content is presented as a financial snapshot for investors interested in the biotechnology stock.
2026-07-27 17:41:21
This article details the shareholder structure of Foghorn Therapeutics Inc. (FHTX), listing its major shareholders and their respective proportions. It also presents institutional shareholding data over several quarters and outlines FHTX's presence in various ETFs.
2026-07-27 10:12:18
This article provides a comprehensive stock analysis of Foghorn Therapeutics Inc. (FHTX) from TradingKey, noting its stable fundamentals, significant growth potential, and "fairly valued" status in the Biotechnology & Medical Research industry. The company has a high institutional ownership, strong buy ratings from multiple analysts with a target price of $11.44, and is currently in a growing phase with a low P/E ratio. Despite recent stock market performance, the company's fundamentals are highlighted as weak, suggesting a sideways trading pattern.
2026-07-27 10:09:37
This article focuses solely on the "Price to sales forward" metric for Foghorn Therapeutics Inc. (NASDAQ:FHTX). The content suggests it is part of a financial data overview provided by TradingView. There are no specific financial figures or analysis presented in the given text.
2026-07-27 10:09:37
This article provides a detailed cash flow statement for Foghorn Therapeutics Inc. (FHTX), covering quarterly and annual data for operating, investing, and financing activities. It includes key financial metrics like net income, capital expenditures, and free cash flow, along with an overview of the company's market performance and FAQs explaining cash flow concepts.
2026-07-26 20:41:46
This article focuses on the enterprise value to revenue forward metric for Foghorn Therapeutics Inc. (NASDAQ: FHTX). It presents this financial data point within the context of the company's stock information on the Nasdaq Stock Market. The content appears to be a stub or a data lookup page from TradingView, providing financial oversight for FHTX.
